Novavax, Inc. (NASDAQ:NVAX) Director Sells $37,433.00 in Stock

Novavax, Inc. (NASDAQ:NVAX) Director Rachel K. King sold 4,150 shares of the firm’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $9.02, for a total value of $37,433.00. Following the completion of the transaction, the director now owns 14,770 shares in the company, valued at approximately $133,225.40. This trade represents a 21.93 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Novavax Stock Performance

Shares of Novavax stock opened at $8.85 on Friday. Novavax, Inc. has a one year low of $3.53 and a one year high of $23.86. The stock’s fifty day moving average is $8.69 and its 200 day moving average is $11.34. The stock has a market cap of $1.42 billion, a P/E ratio of -3.92 and a beta of 2.07.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.07. The business had revenue of $84.51 million for the quarter, compared to the consensus estimate of $65.80 million. Novavax’s revenue was down 54.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.26) earnings per share. Analysts predict that Novavax, Inc. will post -1.44 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on NVAX. B. Riley restated a “buy” rating and issued a $26.00 price target (up from $23.00) on shares of Novavax in a research note on Thursday, October 10th. HC Wainwright restated a “buy” rating and issued a $19.00 price target on shares of Novavax in a research note on Tuesday, December 10th. Finally, Jefferies Financial Group decreased their target price on Novavax from $31.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, October 16th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $17.83.

Institutional Investors Weigh In On Novavax

A number of institutional investors and hedge funds have recently bought and sold shares of NVAX. Banque Cantonale Vaudoise raised its holdings in Novavax by 500.0% during the second quarter. Banque Cantonale Vaudoise now owns 3,000 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 2,500 shares during the period. Amalgamated Bank raised its holdings in Novavax by 26.9% during the second quarter. Amalgamated Bank now owns 4,887 shares of the biopharmaceutical company’s stock valued at $62,000 after acquiring an additional 1,036 shares during the period. Signaturefd LLC grew its position in shares of Novavax by 214.5% during the second quarter. Signaturefd LLC now owns 5,680 shares of the biopharmaceutical company’s stock valued at $72,000 after purchasing an additional 3,874 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Novavax by 38.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 1,598 shares in the last quarter. Finally, Midland Wealth Advisors LLC purchased a new position in shares of Novavax during the second quarter valued at about $152,000. 53.04% of the stock is owned by institutional investors.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.